DI-034 Drug usage evaluation of abiraterone in metastasic castration resistant prostate cancer: 4 Years of experience

BackgroundAbiraterione is an expensive drug indicated for the treatment of metastasic castration resistant prostate cancer. In order to optimise its use, abiraterone is authorised for use under certain criteria in our hospital.PurposeTo analyse compliance with detailed criteria, response to and safe...

Full description

Saved in:
Bibliographic Details
Published in:European journal of hospital pharmacy. Science and practice 2016-03, Vol.23 (Suppl 1), p.A133-A133
Main Authors: Palomares, MV Villacañas, Fernández, EM Sáez, García, G Martín, Domínguez, E Fernández, Hernández, MV Calvo
Format: Article
Language:English
Subjects:
Metastasis
Prostate cancer
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:BackgroundAbiraterione is an expensive drug indicated for the treatment of metastasic castration resistant prostate cancer. In order to optimise its use, abiraterone is authorised for use under certain criteria in our hospital.PurposeTo analyse compliance with detailed criteria, response to and safety of abiraterone in clinical practice in a tertiary hospital.Material and methodsRetrospective observational study of all patients who received abiraterone for 4 years (January 2011–December 2014) through clinical history. Use criteria: performance status: ECOG ≤2 and Gleason < 8, serum transaminase levels
ISSN:2047-9956
2047-9964
DOI:10.1136/ejhpharm-2016-000875.301